Printer Friendly

Bone problems.

Several studies looked at bone mineral density, which is a measurement of bone strength, in HIV+ people. One study examined 272 women (both HIV+ and HIV-negative) and found that HIV+ women ware 3 times more likely to have decreased bone strength (abstract 744). This loss in bone strength can lead to serious bone fractures, such as hip fractures, that can result in an extended hospital stay and the need for physical therapy. In addition, this condition may even lead to fragility fractures. These types of fractures can occur with little or no trauma. According to another study presented at the conference, patients who have fragility fractures commonly have more serious bone fractures later (abstract 743). The affects of Fosamax (alendronate) in treating this loss of bone strength was tested in an "open-label" study, meaning that patients knew which treatment they were receiving (abstract 742). Forty-one HIV+ men and women ware randomly assigned (by chance, like flipping a coin) to receive Fosamax combined with calcium and vitamin D supplements or just calcium and vitamin D supplements. Fosamax had no effect on increasing bone mineral density, but had other beneficial effects.
COPYRIGHT 2004 The Center for AIDS: Hope & Remembrance Project
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:11th Retrovirus Conference Highlights; measurement of bone strength
Publication:HIV Treatment: ALERTS!
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 1, 2004
Words:189
Previous Article:Obesity epidemic.
Next Article:Diabetes risks.
Topics:


Related Articles
Bone--watch out for reversals of fortune.
HIV drug complications in children.
The ABCs of Drug Side Effects.
Conference highlights.
Bones and HIV. (Treatment News).
Position Development Conference. (Special Article).
Antiretroviral pipeline: new-drug reports from retroviruses conference.
This simple laboratory test can give you early information on bone loss.
The truth behind the new depo label.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters